Compounds & Therapies
The Next-Generation GLP-1s: Retatrutide, Survodutide, Pemvidutide, and CagriSema
Four investigational compounds reshaping the weight-loss and metabolic-disease conversation in 2025-2026. What the trials actually showed, where each one differs mechanistically, and how to think about them now versus when they reach the pharmacy.
Tirzepatide (Zepbound, Mounjaro)
Tirzepatide is a synthetic peptide agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. FDA-approved as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic…
Practices & Lifestyle
GLP-1 Receptor Agonists (Semaglutide/Tirzepatide)
Glucagon-Like Peptide-1 Agonists for Metabolic Optimization and Weight Management
Tirzepatide vs Semaglutide vs Retatrutide
The GLP-1 receptor agonist class has revolutionized obesity medicine over the past five years, but "GLP-1" as a single category obscures three quite different products. Semaglutide (Wegovy for obesity, Ozempic for T2D) is a single GLP-1 receptor…